Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Daiichi Sankyo
AstraZeneca
Mallinckrodt
Healthtrust
Cantor Fitzgerald
Covington
Johnson and Johnson
Julphar
Fuji

Generated: January 23, 2018

DrugPatentWatch Database Preview

ERLOTINIB HYDROCHLORIDE Drug Profile

« Back to Dashboard

Which patents cover Erlotinib Hydrochloride, and what generic alternatives are available?

Erlotinib Hydrochloride is a drug marketed by Mylan Pharms Inc and Teva Pharms Usa and is included in two NDAs.

The generic ingredient in ERLOTINIB HYDROCHLORIDE is erlotinib hydrochloride. There are twenty-four drug master file entries for this compound. Three suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the erlotinib hydrochloride profile page.
Drug patent expirations by year for ERLOTINIB HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for ERLOTINIB HYDROCHLORIDE

US Patents and Regulatory Information for ERLOTINIB HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 091002-001 Jun 11, 2014 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 091059-002 Aug 28, 2015 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Pharms Inc ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 091002-002 Jun 11, 2014 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Pharms Inc ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 091002-003 Jun 11, 2014 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 091059-003 Aug 28, 2015 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Medtronic
AstraZeneca
Cantor Fitzgerald
Cipla
Healthtrust
US Department of Justice
Covington
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot